Each filer's latest filing for 68062P106 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
13.8% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 13.8% | |||
| Abigail P. Johnson | 13.8% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
10.0% |
2/14/2025
Event 12/31/2024
|
||
| Paradigm BioCapital Advisors LP | 10.0% | |||
| Paradigm BioCapital Advisors GP LLC | 10.0% | |||
| Senai Asefaw, M.D. | 10.0% | |||
| Paradigm BioCapital International Fund Ltd. | 9.1% | |||
|
Biotechnology Value Fund L P
13D/A
|
9.8% |
10/16/2026
Event 10/14/2026
|
||
| Biotechnology Value Fund L P | 6.6% | |||
| BVF I GP LLC | 6.6% | |||
| Biotechnology Value Fund II LP | 2.7% | |||
| BVF II GP LLC | 2.7% | |||
| Biotechnology Value Trading Fund OS LP | 0.4% | |||
| BVF Partners OS Ltd. | 0.4% | |||
| BVF GP Holdings LLC | 9.1% | |||
| BVF Partners L P/IL | 9.8% | |||
| BVF Inc/IL | 9.8% | |||
| Lampert Mark N | 9.8% | |||
| Hrustanovic Gorjan | 0.2% | |||
| Bain Capital Life Sciences Opportunities IV, L.P. 13G/A | 8.2% |
5/15/2026
Event 3/31/2026
|
||
| Janus Henderson Group Ltd. 13G/A | 7.2% |
11/16/2026
Event 9/30/2026
|
||
| BlackRock, Inc. 13G/A | 7.1% |
7/29/2026
Event 6/30/2026
|
||
|
Invus Global Management, LLC
13G
|
5.1% |
3/20/2026
Event 3/16/2026
|
||
| Invus Public Equities, L.P. | 4.5% | |||
| Invus Public Equities Advisors, LLC | 4.5% | |||
| Invus Global Management, LLC | 4.5% | |||
| Siren, L.L.C. | 4.5% | |||
| Avicenna Life Sci Master Fund LP | 0.6% | |||
| Avicenna Life Sci Master GP LLC | 0.6% | |||
| Ulys, L.L.C. | 0.6% | |||
| Raymond Debbane | 5.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Logos Global Management LP
13D/A
|
4.7% |
5/13/2025
Event 3/18/2025
|
||
| Logos Global Management LP | 4.7% | |||
| Logos Global Management GP LLC | 4.7% | |||
| Arsani William | 4.7% | |||
| Graham Walmsley | 4.7% | |||
| Logos Opportunities GP LLC | 1.0% | |||
| Logos GP LLC | 3.7% | |||
|
Point72 Asset Management, L.P.
13G/A
|
2.3% |
5/15/2025
Event 3/31/2025
|
||
| Point72 Asset Management, L.P. | 2.3% | |||
| Point72 Capital Advisors, Inc. | 2.3% | |||
| Steven A. Cohen | 2.3% | |||
|
Deep Track Capital, LP
13G/A
|
0% |
2/13/2026
Event 12/31/2025
|
||
| Deep Track Capital, LP | 0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | |||
| David Kroin | 0% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 182 | 102 M | $880M |
| 2026 Q2 | 186 | 102 M | $1.28B |
| 2026 Q1 | 203 | 102 M | $1.51B |
| 2025 Q4 | 204 | 90.7 M | $2.27B |
| 2025 Q3 | 130 | 68.3 M | $668M |
| 2025 Q2 | 125 | 70.5 M | $301M |
| 2025 Q1 | 137 | 65.9 M | $248M |
| 2024 Q4 | 160 | 71.3 M | $415M |
| 2024 Q3 | 133 | 58.7 M | $700M |
| 2024 Q2 | 130 | 57.9 M | $627M |
| 2024 Q1 | 128 | 56.1 M | $635M |
| 2023 Q4 | 114 | 51.6 M | $717M |
| 2023 Q3 | 98 | 47.3 M | $584M |
| 2023 Q2 | 88 | 36.4 M | $329M |
| 2023 Q1 | 67 | 33.5 M | $117M |
| 2022 Q4 | 69 | 33.3 M | $81.6M |
| 2022 Q3 | 74 | 33.4 M | $92.1M |
| 2022 Q2 | 77 | 34.2 M | $139M |
| 2022 Q1 | 92 | 36.4 M | $155M |
| 2021 Q4 | 98 | 38.4 M | $360M |
| 2021 Q3 | 79 | 36.7 M | $1.01B |
| 2021 Q2 | 70 | 37.4 M | $1.05B |
| 2021 Q1 | 75 | 35.2 M | $1.16B |
| 2020 Q4 | 58 | 35.1 M | $1.66B |